Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 75.50 GBp
Change Today +2.00 / 2.72%
Volume 314.6K
As of 11:35 AM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Ian R. Garland

Chief Executive Officer, Director and Member of Nominations & Corporate Governance Committee, Vernalis plc
AgeTotal Calculated CompensationThis person is connected to 18 board members in 3 different organizations across 6 different industries.

See Board Relationships
49678,000 GBP
As of Fiscal Year 2013

Background*

Mr. Ian R. Garland has been Chief Executive Officer of Vernalis plc since December 29, 2008. Mr. Garland serves as the Chief Operating Officer of UCB Pharma, Inc. He served as the Chief Executive Officer of Sanofi Pasteur Holding Limited from May 2007 to September 2008. Mr. Garland served as the Chief Financial Officer of Arrow Therapeutics Ltd from June 2004 to 2007. He served as the Chief Financial Officer of Amarin Corp. PLC since March 2003. Mr. Garland joined Amarin ...

Read Full Background

Corporate Headquarters*

100 Berkshire Place
Winnersh, Berkshire RG41 5RD

United Kingdom

Phone: 44 11 8938 0000
Fax: 44 11 8938 0001

Board Members Memberships*

2007-Present
Chief Executive Officer, Executive Director and Member of Nominations Committee
2009-Present
Chief Executive Officer, Director and Member of Nominations & Corporate Governance Committee

Education*

There is no Education data available.

Other Affiliations*

Annual Compensation*

Salary356,000 GBP
Bonus254,000 GBP
Total Annual Compensation610,000 GBP

Stock Options*

All Other Compensation68,000 GBP
Exercisable Options550,089
Exercisable Options Value198,032 GBP
Unexercisable Options9,307,133
Unexercisable Options Value3,022,537 GBP
Total Value of Options3,220,569 GBP
Total Number of Options9,857,222

Total Compensation*

Total Annual Cash Compensation678,000 GBP
Total Short Term Compensation610,000 GBP
Other Long Term Compensation68,000 GBP
Total Calculated Compensation678,000 GBP
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VER:LN 75.50 GBp +2.00

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Rajiv Kanishka Liyanaarchchie De Silva Chief Executive Officer, President and Director
Endo International plc
$1.1M
Clive A. Meanwell M.D., Ph.D.Chairman and Chief Executive Officer
The Medicines Company
$874.6K
Jean-Paul Clozel M.D.Founder, Chief Executive Officer and Director
Actelion Ltd.
SFr.2.7M
Jean-Christophe Tellier Chief Executive Officer and Executive Director
UCB S.A.
--
F. Michael Ball Chief Executive Officer, Director and Member of Science & Technology Committee
Hospira Inc.
$1.1M
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERNALIS PLC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.